16.10.12

Model N launches International Reference Pricing Solution for Global Life Sciences Manufacturers


Solution Combats Price Erosion Stemming from National and Regional Price Control Programs


Redwood Shores, USA - London, UK - Hyderabad, India --- October 11, 2012


Model N, Inc., the leader in Revenue Management solutions, has announced the general availability of its International Reference Pricing (IRP) solution to pharmaceutical manufacturers operating globally.

Model N and the European Pricing Platform (EPP) are close partners since 2009, co-organizing the annual Price and Profit Optimization Forum and providing the Life Sciences industry with thought leadership in the areas of Commercial Strategies, Reference Price Management, Parallel Trade Management, Tender Management, Price Execution and Incentive Management. "The Model N International Reference Pricing platform was first presented at the 2012 Price and Profit Optimization Forum last May in Montreux, Switzerland", said Pol Vanaerde, President of EPP, "and its launch marks an important step in the Model N - EPP partnership".

Model N IRP addresses one of the massive Life Sciences global market challenges


To contain growing healthcare expenditures related to drug costs, a rising number of governments seek to control prices with international reference pricing programs. These programs officially set a drug¡¦s national or regional price based on price benchmarks in other countries. Failing to coordinate price setting at launch and subsequent price changes can result in missed opportunities amounting to tens of millions in revenues. In addition, more and more governments across the globe require that manufacturers proactively report reference prices. Failure to comply in an accurate and timely fashion often puts manufacturers in a weak negotiating position with governments.

Model N International Reference Pricing delivers significant business and operational benefits to pharmaceutical manufacturers by:

  • Supporting data-driven Pricing decisions from pre-launch to launch to growth to maturity, by providing Global and Local teams with full visibility into risks and opportunities associated with future price dynamics
  • Helping Government Affairs teams remain compliant in mandatory governmental price reporting while ensuring Ministries of Health are correctly applying reference rules
  • Connecting Market Access, Pricing and Government Affairs teams around the world in real time enabling efficient collaboration and effective decision-making
  • Increasing pricing data transparency across the entire organization, enabling more accurate financial planning 

Model N IRP has already proven to deliver significant gross margin benefits


"Top Pharmaceutical executives are clear that the new economic reality requires rapid decision-making with integrated collaboration and controls across regions to deal effectively with the needs of International Reference Pricing compliance. Departmental and Excel based solutions will not work. The solution has to be global, unified, real-time and highly collaborative." said Lawrence Whittle SVP Global Sales and Marketing, Model N Inc. "Over the past year, we have worked closely with our pharmaceutical partners to create a robust IRP solution that meets or exceeds these requirements and look forward to helping industry leaders overcome their reference pricing challenges and combat global price erosion."

About Model N International Reference Pricing


Model N International Reference Pricing helps global manufacturers mitigate reference pricing risk and profitability erosion through a powerful combination of data management, software applications, and best practices. Capabilities include:

  • Single Global Repository
  • Global Price Governance and Collaboration
  • End-to-end with data integration, configurations, workflows, analytics, reporting
  • Designed for rapid deployment and time to value of under three months
  • Web Based user interface designed for functional users
  • Subscription-based solution eliminates the need for complex capital acquisition processes or budgets 

Supporting Link

 

Pricing Social Media Links 


Follow Model N on LinkedIn European Life Sciences Price and Profit Optimization Forum 

About Model N 


Model N, the leader in Revenue Management Solutions, drives improved pricing, margin, and revenue performance through a powerful combination of best practices, highly configurable software applications, comprehensive services, and actionable analytics across the complete functional spectrum of pricing, contracting, rebating, sales, and marketing. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and High Tech manufacturers across more than 50 countries. Global Customers include: Allergan, Amgen, Atmel, Boston Scientific, Bristol-Myers Squibb, Dell, Hospira, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, STMicroelectronics, and Watson Pharmaceuticals. Whether you are an emerging business or a global leader, Model N results in revenue.

Model N is a trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.


About the European Pricing Platform


European Pricing Platform (EPP) is a not-for-profit organization and has become the leading knowledge sharing place focusing to support business management, pricing and profit optimization professionals and CxO-level executives in Europe over a variety of industries and sectors. The EPP mission is to be the on- and offline pricing media for international decision makers in a wide range of industries. The interactive collecting, sharing of best practices and development of pricing and profit optimization know-how are the key elements of the platform. EPP is dedicated to the professional development of the individuals and companies involved in the process of pricing and profit optimization. To learn more, visit the website at http://www.pricingplatform.eu

No comments: